1
项与 Everolimus/DTRMWXHS-12/Pomalidomide 相关的临床试验Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.
100 项与 Everolimus/DTRMWXHS-12/Pomalidomide 相关的临床结果
100 项与 Everolimus/DTRMWXHS-12/Pomalidomide 相关的转化医学
100 项与 Everolimus/DTRMWXHS-12/Pomalidomide 相关的专利(医药)
100 项与 Everolimus/DTRMWXHS-12/Pomalidomide 相关的药物交易